Semaglutide

A GLP-1 receptor agonist medication approved for specific medical indications and extensively studied in clinical trials.

Commonly discussed or studied in relation to:

Semaglutide has received significant public attention because of large clinical trials in metabolic and weight-related indications.

Large randomized controlled trials exist for its approved indications, alongside ongoing research in other areas.

Human research: Human studies available.

Approval applies only to specific indications reviewed by regulators. Approval for one indication does not mean it is approved or appropriate for general wellness, beauty, or anti-aging use.

Approval for one specific indication never implies approval or suitability for wellness, cosmetic, or anti-aging uses.

• It has been studied in large, long-duration human trials for defined indications.
• Documented side-effect profiles exist from those trials.

• Long-term outcomes in populations outside studied indications.
• How outcomes differ when used outside a supervised medical context.

• This is a prescription medication; decisions belong with a qualified clinician.
• Compounded or non-pharmacy versions are a distinct regulatory and quality issue.

• What evidence supports this peptide for the goal I'm interested in?
• Is this peptide approved for this particular use?
• What benefits are supported by human evidence?
• What risks or side effects should I understand?
• What important unknowns remain?

• Overview literature relating to semaglutide

  Placeholder — reputable reference to be added · Pending review

• Regulatory status information

  Placeholder — official regulatory source to be added · Pending review

Last reviewed: 2026-08-01